AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28712591 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIOMET (spironolactone 50 mg/d, pioglitazone 7.5 mg/d, metformin 850 mg/d)
Number of subjects: 36
Study 28712591 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIOMET
Number of subjects: 36
Study 28712591 — intervention group
Group type: COMPARATOR
Intervention: OC (ethinylestradiol-levonorgestrel)
Number of subjects: 36
Study 28712591 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 36
Study 25130321 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications associated with weight gain
Number of subjects: 482
Study 25130321 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 482
Study 25130321 — intervention group
Group type: EXPERIMENTAL
Intervention: Early age of onset of bipolar symptoms
Number of subjects: 482
Study 25130321 — intervention group
Group type: EXPERIMENTAL
Intervention: More time spent depressed
Number of subjects: 482
Study 25130321 — intervention group
Group type: EXPERIMENTAL
Intervention: Less time spent manic/hypomanic
Number of subjects: 482
Study 25130321 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of illness
Number of subjects: 482
Study 23230066 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/kg/day iron supplementation (placebo)
Number of subjects: 285
Study 23230066 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day iron supplementation
Number of subjects: 285
Study 23230066 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg/day iron supplementation
Number of subjects: 285
Study 23230066 — intervention group
Group type: COMPARATOR
Intervention: Normal birth weight controls
Number of subjects: 285
Study 21563029 — intervention group
Group type: EXPERIMENTAL
Intervention: Leger equation (E1, 1988)
Number of subjects: 313
Study 21563029 — intervention group
Group type: EXPERIMENTAL
Intervention: Brewer equation (E2, 1988)
Number of subjects: 313
Study 21563029 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 m shuttle run test
Number of subjects: 313
Study 21563029 — intervention group
Group type: COMPARATOR
Intervention: Laboratory test
Number of subjects: 313
Study 18837739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (750 mg daily)
Number of subjects: 22
Study 16557483 — intervention group
Group type: EXPERIMENTAL
Intervention: SJW herb extract (LI‐160) 300 mg once daily
Number of subjects: 28
Study 16557483 — intervention group
Group type: EXPERIMENTAL
Intervention: SJW herb extract (LI‐160) 300 mg twice daily
Number of subjects: 28
Study 16557483 — intervention group
Group type: EXPERIMENTAL
Intervention: SJW herb extract (LI‐160)
Number of subjects: 28
Study 14535628 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day) for 2 months
Number of subjects: 18
Study 14535628 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 18
Study 10735496 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma) 0.1 mg subcutaneously on days 1, 3, 5, 15, 17, and 19 of each 28-day cycle along with 100 mg/m(2) cisplatin and 600 mg/m(2) cyclophosphamide
Number of subjects: 148
Study 10735496 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m(2) and cyclophosphamide 600 mg/m(2)
Number of subjects: 148
Study 10735496 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma)
Number of subjects: 148
Study 10735496 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and cyclophosphamide
Number of subjects: 148
Study 8723395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 0
Study 8723395 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 8723395 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors (class effect)
Number of subjects: 0
Study 8723395 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors (various trials)
Number of subjects: 0
Study 8723395 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0
Study 1414156 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 150 mg/day for patients under 15 years and 300 mg/day for older patients
Number of subjects: 19
Study 1414156 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 19
Study 1414156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3908619 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyadenylic-polyuridylic acid (poly(A).poly(U)) as adjuvant treatment
Number of subjects: 300
Study 3908619 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant treatment)
Number of subjects: 300
Study 31085320 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral CCA filter placement
Number of subjects: 25
Study 27832366 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein drink (PRO 23.9 ± 3.6 g protein)
Number of subjects: 15
Study 27832366 — intervention group
Group type: COMPARATOR
Intervention: Dextrose drink (CHO 26.5 ± 3.8 g carbohydrate)
Number of subjects: 15
Study 26794704 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CP (Opalescence PF; Ultradent Products, Inc)
Number of subjects: 50
Study 26794704 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CP (Power Bleaching 10%)
Number of subjects: 50
Study 26794704 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% CP (Opalescence PF)
Number of subjects: 50
Study 26794704 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% CP (Power Bleaching 16%)
Number of subjects: 50
Study 24861925 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy-Supportive Language (ASL)
Number of subjects: 0
Study 24861925 — intervention group
Group type: COMPARATOR
Intervention: Controlling Language (CL)
Number of subjects: 0
Study 24861925 — intervention group
Group type: COMPARATOR
Intervention: Neutral Language (NL)
Number of subjects: 0
Study 22289570 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (20 g)
Number of subjects: 14
Study 22289570 — intervention group
Group type: COMPARATOR
Intervention: Micellar casein (20 g)
Number of subjects: 14
Study 19833613 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized aspheric IOL (Acri.Smart 36A)
Number of subjects: 43
Study 19833613 — intervention group
Group type: COMPARATOR
Intervention: Zero aberration IOL (Acri.Smart 46LC)
Number of subjects: 43
Study 18049943 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 22
Study 18049943 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy phytoestrogens 55 mg
Number of subjects: 22
Study 18049943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16255136 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy for gastric cancer
Number of subjects: 0
Study 16255136 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant therapy for gastric cancer
Number of subjects: 0
Study 12145148 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 48
Study 12145148 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oils (4 g/day)
Number of subjects: 48
Study 12145148 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with atorvastatin and fish oils
Number of subjects: 48
Study 12145148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10103335 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of Ritalin
Number of subjects: 25
Study 10103335 — intervention group
Group type: EXPERIMENTAL
Intervention: 17.5 mg of Ritalin
Number of subjects: 25
Study 10103335 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of Adderall
Number of subjects: 25
Study 10103335 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg of Adderall
Number of subjects: 25
Study 10103335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8852543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (4 mg once daily)
Number of subjects: 25
Study 8852543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily)
Number of subjects: 25
Study 2177180 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran ingestion
Number of subjects: 16
Study 2177180 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 6773725 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin (1.0 U/kg/h)
Number of subjects: 32
Study 6773725 — intervention group
Group type: COMPARATOR
Intervention: Low-dose insulin (0.1 U/kg/h)
Number of subjects: 32
Study 31696371 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginally delivered HIV prevention product
Number of subjects: 395
Study 31696371 — intervention group
Group type: COMPARATOR
Intervention: Daily-use product
Number of subjects: 395
Study 31696371 — intervention group
Group type: COMPARATOR
Intervention: Insertion by finger
Number of subjects: 395
Study 30732853 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentored simulation training (ST)
Number of subjects: 20
Study 30732853 — intervention group
Group type: COMPARATOR
Intervention: Control group (before ST)
Number of subjects: 20
Study 28094033 — intervention group
Group type: EXPERIMENTAL
Intervention: saline+10μg/ml‐1 vancomycin (vanco group)
Number of subjects: 20
Study 28094033 — intervention group
Group type: COMPARATOR
Intervention: saline (control group)
Number of subjects: 20
Study 25753445 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-led, trained caregiver-delivered, home-based rehabilitation intervention
Number of subjects: 104
Study 25753445 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 104
Study 23406477 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproate extended release (DVA‐ER)
Number of subjects: 300
Study 23406477 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (AMT)
Number of subjects: 300
Study 20718824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 66
Study 20718824 — intervention group
Group type: COMPARATOR
Intervention: Microemulsified cyclosporin (CYA)
Number of subjects: 66
Study 19470865 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy (FS) for saphenous insufficiency
Number of subjects: 1025
Study 19470865 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy (FS)
Number of subjects: 1025
Study 17907494 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Scotchbond Multi‐Purpose (three‐step etch‐and‐rinse)
Number of subjects: 4
Study 17907494 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step (two‐step etch‐and‐rinse)
Number of subjects: 4
Study 17907494 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond (two‐step self‐etching)
Number of subjects: 4
Study 17907494 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III (one‐step self‐etching)
Number of subjects: 4
Study 17907494 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged irradiation time for all adhesives
Number of subjects: 4
Study 17907494 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed adhesive application (after 24 hours or 14 days)
Number of subjects: 4
Study 17907494 — intervention group
Group type: COMPARATOR
Intervention: Control (Unbleached enamel powder)
Number of subjects: 4
Study 15383107 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac suppositories (two x 100 mg)
Number of subjects: 133
Study 15383107 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories (Anusol)
Number of subjects: 133
Study 11195739 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefepime
Number of subjects: 30
Study 11195739 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g cefepime
Number of subjects: 30
Study 9703380 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH infusion (0.33 microg/kg every 90 min for 3 days)
Number of subjects: 19
Study 7927120 — intervention group
Group type: EXPERIMENTAL
Intervention: Suriclone 0.4 mg
Number of subjects: 12
Study 7927120 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 75 mg
Number of subjects: 12
Study 7927120 — intervention group
Group type: EXPERIMENTAL
Intervention: Suriclone 0.4 mg + Imipramine 75 mg
Number of subjects: 12
Study 7927120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2789922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 25 mg folinic acid
Number of subjects: 12
Study 2789922 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 25 mg folinic acid
Number of subjects: 12
Study 2789922 — intervention group
Group type: COMPARATOR
Intervention: Total (‐)‐folates excreted in urine after both routes
Number of subjects: 12
Study 788759 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrallazine (75‐150 mg/day)
Number of subjects: 10
Study 788759 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (60‐120 mg/day)
Number of subjects: 10
Study 788759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31743196 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - 3 cycles of 5‐minute ischemia and 5‐minute reperfusion in right upper limb with cuff pressure at 30 kPa (225 mm Hg)
Number of subjects: 140
Study 31743196 — intervention group
Group type: COMPARATOR
Intervention: Sham RIPC (cuff not inflated)
Number of subjects: 140
Study 29351538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole 960 mg tablets p.o. administered 14 and 2 hours before catheter removal
Number of subjects: 100
Study 29351538 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics administered
Number of subjects: 100
Study 26105567 — intervention group
Group type: EXPERIMENTAL
Intervention: START, then CTAS
Number of subjects: 0
Study 26105567 — intervention group
Group type: COMPARATOR
Intervention: START alone
Number of subjects: 0
Study 23537231 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 160
Study 23537231 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation training
Number of subjects: 160
Study 21739910 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasonography (CDU)
Number of subjects: 75
Study 21739910 — intervention group
Group type: EXPERIMENTAL
Intervention: Multislice computed tomography angiography (MSCTA)
Number of subjects: 75
Study 19951427 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimeticone 4% lotion
Number of subjects: 72
Study 19951427 — intervention group
Group type: COMPARATOR
Intervention: Alternative product (not specified)
Number of subjects: 72
Study 16671929 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent reinforcement (mean 20 s interval)
Number of subjects: 56
Study 16671929 — intervention group
Group type: COMPARATOR
Intervention: Frequent reinforcement (mean 2 s interval)
Number of subjects: 56
Study 16671929 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent reinforcement
Number of subjects: 56
Study 12771924 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk HPV-DNA test (HC2; Hybrid Capture 2)
Number of subjects: 8466
Study 12771924 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine cytology
Number of subjects: 8466
Study 12771924 — intervention group
Group type: COMPARATOR
Intervention: Randomly selected control group (negative findings on both cytology and HPV test)
Number of subjects: 8466
Study 12771924 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative HPV-test result
Number of subjects: 8466
Study 10649147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with counseling materials
Number of subjects: 457
Study 10649147 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 457
Study 9345543 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate pointing to the most recent target
Number of subjects: 8
Study 9345543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pointing to the previous target
Number of subjects: 8
Study 9345543 — intervention group
Group type: COMPARATOR
Intervention: Visual detection of the target without overt responses
Number of subjects: 8
Study 7506145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (100mg twice daily)
Number of subjects: 53
Study 7506145 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500mg twice daily)
Number of subjects: 53
Study 3521255 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine HCl
Number of subjects: 67
Study 3521255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 29708773 — intervention group
Group type: EXPERIMENTAL
Intervention: Fun For Wellness (FFW) intervention
Number of subjects: 479
Study 29708773 — intervention group
Group type: COMPARATOR
Intervention: Usual Care group
Number of subjects: 479
Study 27565018 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antithrombotic therapy with dabigatran etexilate (110 or 150 mg twice daily) and a P2Y12 inhibitor (either clopidogrel or ticagrelor)
Number of subjects: 2500
Study 27565018 — intervention group
Group type: COMPARATOR
Intervention: Triple antithrombotic therapy with warfarin, a P2Y12 inhibitor (either clopidogrel or ticagrelor), and low-dose aspirin (for 1 or 3 months, depending on stent type)
Number of subjects: 2500
Study 25000528 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitate treatment (300 µM) for three days
Number of subjects: 11
Study 25000528 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitate treatment (300 µM) for one day
Number of subjects: 11
Study 22878697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 20
Study 22878697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19910834 — intervention group
Group type: EXPERIMENTAL
Intervention: Total enteral nutrition
Number of subjects: 107
Study 19910834 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 107
Study 18350631 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone plus propranolol (n = 18: Group B)
Number of subjects: 35
Study 18350631 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone (n = 17: Group A)
Number of subjects: 35
Study 15770205 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy/5 fractions (arm A)
Number of subjects: 100
Study 15770205 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gy/2 fractions (arm B)
Number of subjects: 100
Study 15770205 — intervention group
Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 100
Study 14651242 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin cement
Number of subjects: 48
Study 14651242 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer
Number of subjects: 48
Study 14651242 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-oxide-eugenol-free cements
Number of subjects: 48
Study 10809860 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied NG-monomethyl-L-arginine (L-NMMA) in aqueous cream BP
Number of subjects: 17
Study 10809860 — intervention group
Group type: COMPARATOR
Intervention: Aqueous cream BP alone (control)
Number of subjects: 17
Study 8752293 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent rhesus rotavirus-based human rotavirus vaccine
Number of subjects: 0
Study 1802904 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic mixture of lidocaine and prilocaine (EMLA) 5 gm applied for 1 hour before diathermy
Number of subjects: 21
Study 1802904 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied for 1 hour before diathermy
Number of subjects: 21
Study 6882194 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling of the pre-beta lipoprotein band in diabetics (8 cases observed)
Number of subjects: 100
Study 6882194 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 controls chosen at random)
Number of subjects: 100
Study 31513481 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 87
Study 31513481 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 87
Study 29565762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol 50,000 IU (treatment)
Number of subjects: 49
Study 29565762 — intervention group
Group type: COMPARATOR
Intervention: Ergocalciferol 400 IU (control)
Number of subjects: 49
Study 29565762 — intervention group
Group type: COMPARATOR
Intervention: Crossover from control to treatment group (for months 6-10)
Number of subjects: 49
Study 26462724 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (6 mg administered subcutaneously every 2 weeks for 12 weeks)
Number of subjects: 14
Study 26462724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 26462724 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 14
Study 25417120 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-masks used during sleep at night for 24 months
Number of subjects: 300
Study 25417120 — intervention group
Group type: COMPARATOR
Intervention: Control masks (with no light) used during sleep at night for 24 months
Number of subjects: 300
Study 25417120 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-masks
Number of subjects: 300
Study 25417120 — intervention group
Group type: COMPARATOR
Intervention: Control masks
Number of subjects: 300
Study 25417120 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-masks and supplemental oxygen
Number of subjects: 300
Study 22587573 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.5% drops
Number of subjects: 30
Study 22587573 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 30
Study 19799615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-turkey smoking cessation for 24 hours
Number of subjects: 23
Study 19799615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) for 29 days
Number of subjects: 23
Study 19799615 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-smokers (control group)
Number of subjects: 23
Study 17566099 — intervention group
Group type: EXPERIMENTAL
Intervention: ghrelin
Number of subjects: 10
Study 17566099 — intervention group
Group type: EXPERIMENTAL
Intervention: human CRH
Number of subjects: 10
Study 17566099 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine
Number of subjects: 10
Study 17566099 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine with ghrelin
Number of subjects: 10
Study 17566099 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine with CRH
Number of subjects: 10